热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　金斯瑞生物科技（01548）发布截至2024年12月31日止年度业绩，持续经营业务的收益约为5.945亿美元，同比增加6.1%；母公司拥有人应占利润29.62亿美元，上年同期亏损9547.7万美元；每股基本利润139.63美分。

　　期内，收益增加主要是由于：持续投入商业推广（尤其在欧洲和美国）以提升品牌影响力；及推出新的竞争服务和产品，市场份额稳定增长。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.